7th Conference on Retroviruses and Opportunistic Infections


San Francisco, CA - January 30 -February 4, 2000



COMPARISON OF ABDOMINAL FAT DISTRIBUTION IN HIV+ PATIENTS, WITH AND WITHOUT CLINICAL FAT REDISTRIBUTION AND HIV- PATIENTS, USING COMPUTED TOMOGRAPHY.

Conf Retroviruses Opportunistic Infect 2000 Jan 30-Feb 2; 7:79 (abstract no. 22)

P. Burn, S. Comitis, G. Moyle, Y. Miao, C. Baldwin, S. Mandalia, S. Padley, And B. Gazzard
Chelsea and Westminster Hosp., London, UK.

BACKGROUND: Visceral abdominal fat accumulation and subcutaneous fat loss have been reported during antiretroviral therapy. Standardised assessments for this condition are not established.

METHODS: The distribution of subcutaneous (SAT), visceral (VAT), total (TAT) fat, and VAT:TAT ratio in four groups of patients was assessed by single slice CT scan through the umbilicus. The HIV+ patients consisted of 3 groups: clinical fat redistribution syndrome taking protease inhibitors (HIVPI), fat redistribution syndrome on PI-sparing therapy (HIVoPI) and therapy naïve patients without fat redistribution syndrome (HIVn). The control group comprised general radiology patients with previously normal CT examination and no significant medical disorder.

RESULTS: Patients were well matched for age (mean range 37.9-48.6yrs). For HIVPI, HIVoPI and HIVn, median CD4/mm3 (range) were 400 (134-528), 363.5 (211-545) and 65 (19-89), and Log10 viral load((sd) cps/ml)1.32 (0.713), 1.74 (1.02), and 5.30 (0.76), respectively. Adipose tissue results expressed as a mean (95% confidence intervals in brackets below), or as a median (†) and inter quartile range as appropriate; p-values by Kruskal-Wallis test. For HIVPI (n=19) HIVoPI (n=7), HIVn (n=12) and Control (n=14) values are SAT(cm2) † 65.6(26-122), 72.9(45-142), 62.8(34-94), 155.3(111-204), for VAT(cm2) 139.4(111-168), 161.5(101-222), 49.3(32-67), 102.7(69-137), for TAT(cm2) 220.3(172-269), 245.8(169-322), 128.5(68-189), 260.7(208-314)and for VAT:TAT 0.66(0.58-0.75), 0.66(0.51-0.80), 0.44(0.33-0.56) and 0.37(0.29-0.45), respectively. Significant differences were observed between SAT, VAT, TAT and VAT/TAT between the four groups of patients (p=0.0011, 0.0001, 0.0064 and 0.0001 respectively). HIV patient groups on- therapy with clinical both had a significantly higher VAT:TAT than controls whereas therapy naïve patients had a similar VAT:TAT to controls.

CONCLUSIONS: Patients with clinical fat redistribution are distinguishable from controls by VAT:TAT measurement. Abdominal fat accumulation can occur in patients taking anti-retroviral therapy independent of protease inhibitor therapy.

Keywords: AEGIS, Tomography, X-Ray Computed, Abdomen, Adipose Tissue, Obesity, Fats, Viscera, HIV Infections, Thoracic Surgery, Video-Assisted, Endocrine Diseases, Anti-HIV Agents, Metabolism, Inborn Errors, Antithrombin III, Case-Control Studies, antithrombin III-protease complex, Human, utilization, supply & distribution, radiography, AIDS

Acrobat Reader Download PDF logo

2000-01-30
22

Copyright © 2000 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.